BioNJ’s 13th Annual C-Suite Summit will be held on Oct. 30, at the Bridgewater Marriott, bringing together a premier lineup of executive leaders to address the most pressing strategic challenges facing the life sciences industry.
The Summit will convene top executives from emerging startups, established global players, and public and private organizations to foster high-level connections and candid dialogue. The event comes as the life sciences landscape is defined by AI-powered advancements, shortened product lifecycles, economic uncertainty, and geopolitical shifts.
“It’s a pivotal moment to reflect, regroup and reimagine what’s possible for the future of life sciences,” Debbie Hart, president and CEO of BioNJ said. “In this unprecedented era of policy challenges and industry scrutiny, the Summit serves as a crucial platform for leaders to unite and safeguard the future of innovation while expanding patient access.”
Premier speaker roster and action-packed agenda
The event features a world-class speaker roster from influential organizations across the life sciences spectrum, including:
- Liz Barrett (CEO, UroGen Pharma)
- Dr. Michael Cantor, (VP, Data Technology & Innovation, Regeneron)
- Hisham Hamadeh, Ph.D. (SVP, Global Head, Data, Digital & AI, Genmab)
- Dr. Matthew Klein, (CEO, PTC Therapeutics)
- Chris Mortko, Ph.D. (VP, Head Search & Evaluation, Business Development & Licensing, Merck & Co.)
- Nauman Shah (Global Head, J&J Innovative Medicine Business Development, Johnson & Johnson)
- Arda Ural, Ph.D. (Americas Life Sciences Leader, EY)
The agenda is structured around critical topics designed to help executives navigate turbulence and plan for future growth:
- Implications of Generative AI in Biopharma
- Navigating Biopharma’s Challenging Financial Landscape
- Evolving Capital Markets & Implications for the Biopharma Ecosystem
- Accelerating Patient-Centric Innovation in R&D
- Navigating the Future of Deal Making in Biopharma
- How Culture-Driven Leadership Creates Strategic Options
The Summit offers substantial networking opportunities, including direct access to speakers, aiming to foster “authentic dialogue and lasting relationships among executive decision-makers and forward-thinking innovators.”
Registration for the event is $695 for BioNJ Members and $895 for Future Members. The organization noted that the Summit is closed to Media.
Click here for the full agenda.
Click here to register.
